Tice BCG

Cytostatic · Live attenuated strain of mycobacterium bovis

Indications

Treatment of primary or relapsing flat urothelial cell carcinoma in situ (TIS) of the bladder. As an adjuvant therapy after TUR of a primary or relapsing superficial urothelial cell carcinoma of the bladder (See literature).

Dosage

BRAND: ONCOTICE: Adults: For instillation the contents of one ampoule of OncoTICE, reconstituted and diluted as indicated, are instilled in the urinary bladder. If OncoTICE is used as an adjuvant therapy after TUR of superficial urothelial cell carcinoma of the bladder, the OncoTICE therapy should be started between 10 and 15 days after performing the TUR. Both the OncoTICE therapy for treatment of Tis of the bladder and the OncoTICE adjuvant therapy after TUR of superficial urothelial cell carcinoma of the bladder comprise the weekly instillation of OncoTICE for 6 consecutive wk. This schedule may be repeated once if the clinical circumstance warrant. Subsequently it can be followed by a maintenance treatment. The maintenance treatment course should be started after a treatment free interval of 4 to 6 wk following termination of the initial 6 wk treatment period. During the maintenance…

Adverse Effects

Symptoms of bladder irritation, like dysuria, urinary frequency and hematuria develop in the majority of the patients. The cystitis and typical inflammatory reactions (Granulomatous) which occur in the mucosa of the urinary bladder after instillation of BCG and which cause these symptoms, may be an essential part of the anti-tumour activity of the BCG instillation. During the maintenance treatment course, the symptoms of cystitis may be more pronounced and prolonged. Malaise, a low grade fever and/or a flu like syndrome. Fever higher than 39°C. Systemic infection due to traumatic catheterization, bladder perforation or early BCG instillation after extensive TUR of urothelial cell carcinoma. Granulomatous prostatitis. In rare cases, arthritis/arthralgia, major haematuria, skin rash, transient urethral obstruction, orchitis or bladder contracture may occur.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Precautions: Should not be administered IV or SC or IM. Before the first intravesical instillation, a Mantoux test (PPD) should be performed. In case this test is positive, the intravesical instillation is contra-indicated only if there is supplementary medical evidence for an active tuberculous infection. Traumatic catheterization can promote systemic BCG infection. Delaying administration should be considered in such patients until mucosal damage has been healed. In patients with known risk factors for HIV infection, perform adequate HIV assays prior to therapy.

Advice to Patient

Injected under the supervision of expert medical practitioner only. Lay down on your front for the first 15 minutes after receiving Tice BCG. Do not take any fluids 4 hours before treatment. For 6 hours after treatment, urinate in a seated position. Drink plenty of fluids after first urination unless restricted by prescriber. Avoid contact with people who have cold or infections. Contact prescriber if there is any allergic reaction (rash, itching, hives, difficulty in breathing, swelling on face/lips/tongue/throat), frequent or less urination, pain on urination, blood in urine, loss of appetite, nausea, tiredness, diarrhoea, fever, chills, cough, sore throat, joint or muscle pain, unusual bruising/bleeding, unusual tiredness/weakness, severe nausea or vomiting, yellowing of the skin or white part of eyes, fast heartbeat, changes in vision, redness/swelling/pain in eye, photosensitivity,…

Pharmacokinetics

Excretion: Urine.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.